The Effects of GLA (5 mcg) on Human Volunteers

NCT01864876 | Completed Phase 1

• 1 other identifier: MCA-0784
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

This protocol is for a phase 1, randomized, single-blinded study to evaluate the safety and tolerability of a single 5 mcg dose of GLA-SE administered intramuscularly and GLA-AF administered subcutaneously. The second focus will be to detail the global immune response by measuring systemic cytokines, chemokines, and global gene regulation. The third focus will be to investigate the effects of GLA on the peripheral blood immune cells including monocytes and dendritic cells. The results of this trial will generate supportive human data to use GLA as an adjuvant in a dendritic cell-targeted vaccine strategy.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (1)

• Safety

  Local reactogenicity events and systemic reactogenicity events will be monitored for 28 days post injection. * Local reactogenicity events include tenderness, erythema, skin discoloration, edema, vesicle formation or ulceration, induration, pruritus, formation of a crust or scab, or other. * Systemic reactogenicity events include fever, chills, headache, nausea, vomiting, malaise, myalgia, arthralgia, and rash. Long term safety will be monitored by follow-up phone calls at 3 months, 6 months, and 1 year post injection.

  1 year

Secondary Outcomes (1)

• Immunogenicity

  28 days

Study Arms (3)

GLA-AF

EXPERIMENTAL

5 mcg GLA-AF given as one subcutaneous injection.

Biological: GLA-AF

GLA-SE

EXPERIMENTAL

5 mcg GLA-SE given as one intramuscular injection.

Biological: GLA-SE

EM060G (SE)

EXPERIMENTAL

EM060G (SE) given as one intramuscular injection.

Biological: EM060G (SE)

Interventions

GLA-AF BIOLOGICAL

Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).

GLA-AF

GLA-SE BIOLOGICAL

Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).

GLA-SE

EM060G (SE) BIOLOGICAL

The same stable oil-in-water emulsion (SE), but without GLA.

EM060G (SE)

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult males and females, as assessed by a medical history, physical exam,and laboratory tests;
• Age of at least 18 years of age on the day of screening and no greater than 50 years at time of administration;
• Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 4 weeks);
• Willing to undergo HIV testing and counseling and receive HIV test results;
• If a female of child bearing potential, must be willing to use two effective methods of contraception (combined oral contraceptive pill; injectable contraceptive; diaphragm; Intra Uterine Device (IUD); condoms; anatomical sterility in self or partner) until 6 weeks after study drug administration. If a sexually active male, must be willing to use two effective methods of contraception (such as condoms, anatomical sterility) from screening until 6 weeks after study drug administration (same as above) and will be advised not to get his partner(s) pregnant during this time.

You may not qualify if:

• Positive for hepatitis B surface antigen, positive for hepatitis C antibodies, or active syphilis infection based on clinical evaluation;
• Confirmed HIV-1 or HIV-2 infection;
• Any clinically significant abnormality on medical history or physical examination including history of immunodeficiency or autoimmune disease;
• Any use of systemic corticosteroids immunosuppressive anticancer medications;
• Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that in the opinion of the investigator would preclude participation;
• Any laboratory value outside of reference range other than CRP, with the exception of any non-clinically significant Grade I elevations of liver function tests (AST, ALT, direct/total bilirubin), electrolytes (Na, K, Cl, CO2), CBC, urinalysis as determined by the Principal Investigator or his designee.
• Within the 12 months prior to enrollment, the subject self reports excessive daily alcohol use, frequent binge drinking or chronic marijuana abuse (defined as greater than 2 times a week) or any other use of illicit drugs;
• If female, pregnant, planning a pregnancy during the trial period, or lactating;
• Receipt of a live attenuated vaccine within 30 days or other vaccine within 14 days prior to study drug;
• Prior receipt of GLA in another research study;
• Participation in another clinical study of an investigational product currently or within past 16 weeks, or expected participation during this study;
• In the opinion of the investigator, unlikely to comply with protocol due to medical, social or psychiatric reasons;
• Allergy to eggs
• A glomerular filtration rate that is less than 60 mL/min/1.73 m2 as calculated by study team based on laboratory creatinine values.

Sponsors & Collaborators

• Access to Advanced Health Institute (AAHI): lead
• Rockefeller University: collaborator

Study Sites (1)

Rockefeller University

New York, New York, 10065, United States

Location

MeSH Terms

Interventions

GLA-AF adjuvant; glucopyranosyl lipid-A

Study Officials

• Franco Piazza, MD, MPH

  Access to Advanced Health Institute (AAHI)

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 24, 2013
• First Posted: May 30, 2013
• Study Start: September 1, 2012
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2013
• Last Updated: February 26, 2014

Record last verified: 2014-02

Locations

US (1)